Popular Articles
Revitol Cellulite Cream

Lethality Of H1N1 Influenza Virus Increasing According To Latest Analysis Of Virus Peptide Genomic Data
An analysis of the latest peptide genomic data for the H1N1 influenza virus indicates that the current global outbreak of H1N1 is increasing in its capacity for lethality. The new sequence data on PubMed of the past two weeks through June 10, 2009 showed an increase in the Replikin Count* of the Replikin Lethality Gene in the pB1 genomic area from a mean of 2+/-0.2 in 2008 to a mean of 3.2+/-3.7 in 2009 (p Don't forget to buy zoloft online no prescription.

HELP Democrats Draft New Bill With Public Plan And Employer Mandate That They Say Is Cheaper
Democrats on a key Senate committee are readying a plan that has a government-run insurance option and a $750-per-worker annual fee on larger companies that do not offer coverage to its employees, The Associated Press reports.

generic viagra online


News of the day
Legislation Protecting Patients From Losing Health Insurance When They Get Sick Clears Senate Policy Committee
Legislation protecting patients from the practice of health insurers and health plans canceling their coverage when they get seriously ill today passed the Senate Judiciary Committee.
Oncology

Meridian Bioscience Receives FDA Clearance For New Rapid Campylobacter Test

Meridian Bioscience, Inc. (NASDAQ: VIVO) announced that it has received FDA clearance from the U.S. Food and Drug Administration (FDA) for a new rapid test for Campylobacter, ImmunoCard STAT!® CAMPY. This new test provides fast and accurate detection of Campylobacter bacteria, one of the most common causes of diarrheal illness and the most common bacterial cause of foodborne illness in the United States. Approximately 20 million stool culture tests are conducted each year in the U.S. to detect the illness, known as Campylobacteriosis. Campylobacter is most often transmitted by poorly cooked poultry or person-to-person contact. There is a real need for the ImmunoCard STAT!® CAMPY because of its simplified, easy to perform procedure that provides patient results in 20 minutes. In addition, ImmunoCard STAT!® CAMPY provides a solution to several concerns associated with culture testing, currently the most commonly practiced lab technique for detecting the Campylobacter bacteria. With culture, there is a potential for reduction in sensitivity due to variable culturing procedures, specimen viability, and inhibitory antibiotics in culture media. ImmunoCard STAT!® CAMPY dramatically reduces these concerns with a consistent method that measures the bacterial antigen instead of measuring the viability of this fragile bacteria in an environment that is less inhibitory than current culturing procedures. John A. Kraeutler, Chief Executive Officer, stated, "ImmunoCard STAT!® CAMPY is a significant addition to our foodborne category because it provides laboratories with a rapid, accurate and easy to perform platform for the detection of Campylobacter. This innovative assay, along with Meridian"s Premier™ CAMPY and toxigenic E. coli tests, demonstrates Meridian"s emerging leadership in foodborne testing. ImmunoCard STAT!® CAMPY is already in distribution by Meridian Bioscience Europe for the Company"s European markets and was also recently approved for sale in Canada." Meridian Bioscience, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):